Testosterone Replacement in the Prostate Cancer Patient

Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005 Feb;173(2):533-6. http://www.ncbi.nlm.nih.gov/pubmed/15643240

Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010 Jul 8;363(2):109-22. http://www.ncbi.nlm.nih.gov/pubmed/20592293

Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010 http://www.ncbi.nlm.nih.gov/pubmed/16720669

Carroll P, Coley C, McLeod D, et al. Prostate-specific antigen best practice policy–part I: early detection and diagnosis of prostate cancer. Urology. 2001 Feb;57(2):217-24. http://www.ncbi.nlm.nih.gov/pubmed/11182324

Conners WP 3rd, Morgentaler A. The evaluation and management of testosterone deficiency: the new frontier in urology and men’s health. Curr Urol Rep. 2013 Dec;14(6):557-64. http://www.ncbi.nlm.nih.gov/pubmed/23999611

Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010 May;64(6):682-96. http://www.ncbi.nlm.nih.gov/pubmed/20518947

English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102(16):1906-11. http://www.ncbi.nlm.nih.gov/pubmed/11034937

English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000 Jun;21(11):890-4. http://www.ncbi.nlm.nih.gov/pubmed/10806012

Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014 Jan 29;9(1):e85805. http://www.ncbi.nlm.nih.gov/pubmed/24489673

Gooren LJ, Behre HM, Saad F,  et al. Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male. 2007 Dec;10(4):173-81 http://www.ncbi.nlm.nih.gov/pubmed/18033626

Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007 Jan;82(1):29-39 http://www.ncbi.nlm.nih.gov/pubmed/17285783

Hak AE, Witteman JC, de Jong FH, et al.  Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9. http://www.ncbi.nlm.nih.gov/pubmed/12161487

Hijazi RA, Cunningham GR. Andropause: is androgen replacement therapy indicated for the aging male? Annu Rev Med. 2005;56:117-37. http://www.ncbi.nlm.nih.gov/pubmed/15660505

Jannini EA, Gravina GL, Morgentaler A, et al. Is testosterone a friend or a foe of the prostate? J Sex Med. 2011 Apr;8(4):946-55. http://www.ncbi.nlm.nih.gov/pubmed/21457469

Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology. 2013 Aug;82(2):321-6. http://www.ncbi.nlm.nih.gov/pubmed/23706552

Khera M, Crawford D, Morales A, et al. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol. 2014 Jan;65(1):115-23. http://www.ncbi.nlm.nih.gov/pubmed/24011426

Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009 Apr;6(4):1165-70. http://www.ncbi.nlm.nih.gov/pubmed/19207277

Maggi M, Schulman C, Quinton R, et al. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007 Jul;4(4 Pt 1):1056-69. http://www.ncbi.nlm.nih.gov/pubmed/17627750

McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003 Jan;91(1):69-74. http://www.ncbi.nlm.nih.gov/pubmed/12614254

Miner MM, Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med. 2007 May;74 Suppl 3:S38-46. http://www.ncbi.nlm.nih.gov/pubmed/17549824

Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6. http://www.ncbi.nlm.nih.gov/pubmed/8968017

Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul;60(7):762-9. http://www.ncbi.nlm.nih.gov/pubmed/16846397

Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Oct 21;169(6):725-33. http://www.ncbi.nlm.nih.gov/pubmed/23999642

Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):261-6. http://www.ncbi.nlm.nih.gov/pubmed/17113983

Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004 Jan 29;350(5):482-92. http://www.ncbi.nlm.nih.gov/pubmed/14749457

Shelton JB, Rajfer J. Androgen deficiency in aging and metabolically challenged men. Urol Clin North Am. 2012 Feb;39(1):63-75.  http://www.ncbi.nlm.nih.gov/pubmed/22118346

Shores MM, Matsumoto AM, Sloan KL, et al. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006 Aug 14-28;166(15):1660-5. http://www.ncbi.nlm.nih.gov/pubmed/16908801

Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012 Jun;97(6):2050-8. http://www.ncbi.nlm.nih.gov/pubmed/22496507

Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with lowtestosterone levels. JAMA. 2013 Nov 6;310(17):1829-36. http://www.ncbi.nlm.nih.gov/pubmed/24193080

Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009 Jan-Feb;30(1):1-9. http://www.ncbi.nlm.nih.gov/pubmed/18772485

Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999 Oct 19;100(16):1690-6. http://www.ncbi.nlm.nih.gov/pubmed/10525487

Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014 Jan;99(1):E9-18. http://www.ncbi.nlm.nih.gov/pubmed/24257908